X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (56782) 56782
Book Chapter (482) 482
Dissertation (133) 133
Government Document (122) 122
Publication (54) 54
Reference (46) 46
Conference Proceeding (45) 45
Newsletter (36) 36
Newspaper Article (30) 30
Book / eBook (17) 17
Magazine Article (17) 17
Web Resource (3) 3
Trade Publication Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32157) 32157
growth-factor receptor (25567) 25567
oncology (17655) 17655
animals (15262) 15262
female (13893) 13893
cancer (12113) 12113
male (10889) 10889
epidermal growth factor receptors (9793) 9793
expression (8641) 8641
epidermal growth factor receptor (8124) 8124
middle aged (7951) 7951
epidermal growth factor (7868) 7868
mutation (7488) 7488
biochemistry & molecular biology (7405) 7405
mice (7313) 7313
signal transduction (7293) 7293
cell biology (7038) 7038
aged (6862) 6862
tumors (6503) 6503
adult (6122) 6122
cell line, tumor (5895) 5895
chemotherapy (5763) 5763
proteins (5471) 5471
phosphorylation (5450) 5450
research (5297) 5297
kinases (5292) 5292
egfr (5064) 5064
gene expression (4715) 4715
analysis (4662) 4662
prognosis (4621) 4621
apoptosis (4572) 4572
lung cancer (4545) 4545
receptor, epidermal growth factor - metabolism (4529) 4529
activation (4522) 4522
immunohistochemistry (4328) 4328
gefitinib (4255) 4255
metastasis (4190) 4190
care and treatment (4057) 4057
genetic aspects (3947) 3947
multidisciplinary sciences (3832) 3832
breast cancer (3818) 3818
patients (3656) 3656
receptor, epidermal growth factor - genetics (3607) 3607
survival (3582) 3582
tyrosine (3519) 3519
pharmacology & pharmacy (3495) 3495
growth factors (3481) 3481
health aspects (3445) 3445
antineoplastic agents - therapeutic use (3429) 3429
medicine (3427) 3427
research article (3282) 3282
aged, 80 and over (3180) 3180
cells (3168) 3168
growth-factor-receptor (3139) 3139
cell proliferation (3124) 3124
therapy (3079) 3079
pathology (2933) 2933
lung neoplasms - genetics (2882) 2882
cancer therapies (2802) 2802
receptor, epidermal growth factor - antagonists & inhibitors (2785) 2785
lung neoplasms - drug therapy (2764) 2764
angiogenesis (2755) 2755
antineoplastic agents - pharmacology (2727) 2727
breast-cancer (2673) 2673
science (2593) 2593
rats (2562) 2562
adenocarcinoma (2554) 2554
vascular endothelial growth factor (2533) 2533
lung neoplasms - pathology (2511) 2511
medicine, research & experimental (2484) 2484
cell lung-cancer (2466) 2466
treatment outcome (2455) 2455
erlotinib (2437) 2437
studies (2401) 2401
physiological aspects (2400) 2400
development and progression (2394) 2394
signal transduction - drug effects (2375) 2375
carcinoma (2343) 2343
mutations (2340) 2340
risk factors (2331) 2331
inhibition (2303) 2303
tyrosine kinase inhibitor (2289) 2289
cetuximab (2280) 2280
tyrosine kinase (2223) 2223
carcinoma, non-small-cell lung - drug therapy (2211) 2211
biomarkers (2210) 2210
biology (2208) 2208
medical prognosis (2193) 2193
protein (2172) 2172
glomerular filtration rate (2170) 2170
gene (2162) 2162
medicine & public health (2157) 2157
cell line (2146) 2146
cells, cultured (2135) 2135
metastases (2109) 2109
gene expression regulation, neoplastic (2092) 2092
ligands (2086) 2086
proliferation (2039) 2039
surgery (2020) 2020
genes (2018) 2018
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (55881) 55881
Chinese (951) 951
Japanese (755) 755
French (226) 226
German (172) 172
Korean (85) 85
Spanish (83) 83
Portuguese (52) 52
Polish (36) 36
Russian (36) 36
Norwegian (16) 16
Turkish (14) 14
Czech (9) 9
Hungarian (8) 8
Italian (8) 8
Dutch (6) 6
Persian (4) 4
Lithuanian (3) 3
Danish (2) 2
Swedish (2) 2
Croatian (1) 1
Nauru (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer research (Chicago, Ill.), ISSN 1538-7445, 2017, Volume 77, Issue 10, pp. 2712 - 2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | ONCOLOGY | ADENOCARCINOMAS | RESISTANCE | OPEN-LABEL | MUTATIONS | TUMORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Molecular Conformation | Receptor, ErbB-2 - chemistry | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Codon | Adult | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Gene Expression | Models, Molecular | Treatment Outcome | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Mutagenesis, Insertional | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | Amino Acid Substitution | Epidermal growth factor receptors | Lung cancer | Insertion | Non-small cell lung carcinoma | Drug resistance | Patients | ErbB-2 protein | Mutants | Sensitivity | Covalence | Inhibitors | Mutation | Tumors | Cancer | human epidermal growth factor receptor 2 | drug resistance | tyrosine kinase inhibitor | exon 20 | Epidermal growth factor receptor
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2002, Volume 95, Issue 11, pp. 2373 - 2379
BACKGROUND Desmoid tumor represents a rare monoclonal neoplasm arising from deep musculoaponeurotic structures and may occur sporadically or in association... 
tyrosine kinase inhibition | platelet‐derived growth factor receptor‐β (PDGFR‐β) | imatinib mesylate | chemotherapy | platelet‐derived growth factor receptor‐α (PDGFR‐α) | c‐kit | desmoid tumor | Chemotherapy | Platelet-derived growth factor receptor-α (PDGFR-α) | Tyrosine kinase inhibition | Imatinib mesylate | Platelet-derived growth factor receptor-β (PDGFR-β) | C-kit | Desmoid tumor | MANAGEMENT | platelet-derived growth factor receptor-alpha (PDGFR-alpha) | c-kit | BCR-ABL | AGGRESSIVE FIBROMATOSIS | RADIATION-THERAPY | ONCOLOGY | GROWTH | TYROSINE KINASE INHIBITOR | FAMILIAL ADENOMATOUS POLYPOSIS | platelet-derived growth factor receptor-beta (PDGFR-beta) | ASSOCIATION | REMISSION | Receptor, Platelet-Derived Growth Factor beta - drug effects | Humans | Salvage Therapy | Male | Treatment Outcome | Proto-Oncogene Proteins c-kit - drug effects | Pyrimidines - pharmacology | Proto-Oncogene Proteins c-kit - biosynthesis | Imatinib Mesylate | Piperazines - pharmacology | Fibroma - pathology | Adolescent | Adult | Antineoplastic Agents - pharmacology | Benzamides | Fibroma - drug therapy | Fibromatosis, Aggressive - pathology | Fibromatosis, Aggressive - drug therapy | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Cancer patients | Care and treatment | Oncology, Experimental | Analysis | Drug therapy | Health aspects | Abdomen | Cancer
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2005, Volume 102, Issue 40, pp. 14344 - 14349
Journal Article
PloS one, ISSN 1932-6203, 2010, Volume 5, Issue 11, p. e14117
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all will develop resistance and relapse. Gene expression... 
Fibroblast Growth Factor 7 - pharmacology | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Coculture Techniques | Humans | Lung Neoplasms - metabolism | Fibroblast Growth Factor 2 - pharmacology | Lung Neoplasms - pathology | Extracellular Signal-Regulated MAP Kinases - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Fibroblasts - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Drug Resistance, Neoplasm - genetics | Signal Transduction - drug effects | Fibroblasts - drug effects | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Fibroblasts - cytology | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Tyrosine | Phenols | Fibroblast growth factors | RNA | Analysis | Luciferase | Fibroblast growth factor | Biotechnology | Transcription | Gene regulation | Lung cancer | Biology | Kinases | Cell adhesion & migration | Morphogenesis | Epidermal growth factor | Fibroblast growth factor receptor 7 | Gefitinib | Protein-tyrosine kinase | Fibroblast growth factor receptor 2 | Fibroblast growth factor 2 | Epidermal growth factor receptors | Extracellular signal-regulated kinase | Non-small cell lung carcinoma | Gene expression | Src protein | Self sufficiency | Pulmonary hypertension | Studies | Signaling | Inhibitors | Monoclonal antibodies | Ligands | Mutation | Tumors | Fibroblast growth factor receptors
Journal Article
PloS one, ISSN 1932-6203, 09/2016, Volume 11, Issue 9, p. e0162594
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 7, pp. 1115 - 1123
BACKGROUND The 2013 testing guidelines for determining the human epidermal growth factor receptor 2 (HER2) status include new cutoff points for the... 
invasive breast cancer | Smith‐Magenis syndrome (SMS) and retinoic acid receptor α (RARA) genes as alternative chromosome 17 genes | equivocal human epidermal growth factor receptor 2 (HER2) results | prognostic significance of equivocal human epidermal growth factor receptor 2 (HER2) results | alternative chromosome 17 genes in determining human epidermal growth factor receptor 2 (HER2) status | Smith-Magenis syndrome (SMS) and retinoic acid receptor α (RARA) genes as alternative chromosome 17 genes | prognostic significance of equivocal human epidermal | Smith-Magenis syndrome (SMS) and retinoic acid receptor alpha (RARA) genes as alternative chromosome 17 genes | POLYSOMY 17 | IN-SITU HYBRIDIZATION | CENTROMERE | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | AMPLIFICATION | THERAPY | ONCOLOGY | COPY NUMBER | HER2 STATUS | growth factor receptor 2 (HER2) results | AMERICAN SOCIETY | Immunohistochemistry | Prognosis | Receptor, ErbB-2 - genetics | Humans | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Biomarkers, Tumor | Chromosomes, Human, Pair 17 - genetics | DNA Copy Number Variations | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Female | Breast Neoplasms - diagnosis | Cohort Studies | Usage | Breast cancer | Research | Reflexes | Testing | Enumeration | Copy number | Invasiveness | Genes | Fluorescence | Hazards | Regression analysis | Patients | Survival | ErbB-2 protein | Confidence intervals | Epidermal growth factor | Fluorescence in situ hybridization | Clinical medicine | Probes | Chromosomes | Retinoic acid | Chromosome 17 | Cancer
Journal Article